Bioequivalence Study on Loratadine Orally Disintegrating Tablets 10 mg Under Fasting Conditions
Status:
Completed
Trial end date:
2006-09-01
Target enrollment:
Participant gender:
Summary
To compare the single-dose oral bioavailability of loratadine 10 mg orally disintegrating
tablets of Ohm Laboratories (a subsidiary of Ranbaxy Pharmaceuticals Inc., USA) with
Claritin® Reditabs® (containing loratadine 10 mg) of Schering-Plough Healthcare Product Inc.,
USA in healthy, adult, human male subjects under fasting condition.